Skip to main content

Advertisement

Table 1 Clinical data of 238 nasopharyngeal carcinoma patients

From: Evaluation of effect of body mass index and weight loss on survival of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy

   Pre-treatment BMI, kg/m2
Variable All <23 (N = 81) ≥23 (N = 157) p
Age, y 50.26 ± 11.82 49.02 ± 12.84 50.09 ± 11.24 0.246
Sex (%)     <0.001
 male 169(71.0) 45(55.6) 124(79.0)  
 female 69(29.0) 36(44.4) 33(21.0)  
Smoke (%)     0.106
 No 160(67.2) 60(74.1) 100(63.7)  
 Yes 78(32.8) 21(25.9) 57(36.3)  
CCIS (%)     0.742
 0 184(77.3) 64(79.0) 120(76.4)  
 1 32(13.4) 9(11.1) 23(14.6)  
 ≥2 22(9.2) 8(9.9) 14(8.9)  
Histology type     0.082
 NUC 214(89.9) 69(85.2) 145(92.4)  
 NDC 24(10.1) 12(14.8) 12(7.6)  
T classification (%)     0.253
 T1/T2 121(50.8) 37(45.7) 84(53.5)  
 T3/T4 117(49.2) 44(54.3) 73(46.5)  
N classification (%)     0.779
 N0/N1 62(26.1) 22(27.2) 40(25.5)  
 N2/N3 176(73.9) 59(72.8) 117(74.5)  
AJCC Stage (%)     0.775
 Stage 1/2 36(15.1) 13(16.0) 23(14.6)  
 Stage 3/4 202(84.9) 68(84.0) 134(85.4)  
Treatment arm (%)     0.592
 RT alone 41(17.2) 15(18.5) 26(16.6)  
 CCRT alone 93(39.1) 28(34.6) 65(41.4)  
 RT/CCRT + CT 104(43.7) 38(46.9) 66(42.0)  
BWL (%)     0.003
 <5 % 88(37.0) 41(50.6) 47(29.9)  
 ≥5 % 150(63.0) 40(49.4) 110(70.1)  
Education level (%)     0.97
 Low 113(47.5) 39(48.1) 74(47.1)  
 Medium 70(29.4) 23(28.4) 47(29.9)  
 High 55(23.1) 19(23.5) 36(22.9)  
 RT duration 7.46 ± 0.77 7.58 ± 0.80 7.40 ± 0.75 0.091
 Hemoglobin 13.85 ± 1.77 13.28 ± 1.66 14.15 ± 1.75 0.001
  1. CCIS Charlson Comorbidity Index Score; NUC nonkeratinizing undifferentiated carcinoma; NDC nonkeratinizing differentiated carcinoma; BMI body mass index; BWL body weight loss; RT radiotherapy; CT chemotherapy; CCRT concurrent chemoradiotherapy
  2. Values are numbers (percentage)